When a patient enters the emergency department in critical condition, doctors must quickly run through a crucial list of questions: Does the patient have an infection? If so, is it bacterial or viral? Do they require treatment? Can the patient recover at home safely or do they need to be hospitalized?

Even when an infection is diagnosed, the treatment plan isn’t always clear.

The research, led by Dr André Brown and the Behavioural Phenomics group at the LMS, was published last week in BMC Biology. It represents a step toward solving a major challenge in medicine: how to develop treatments for the thousands of rare genetic diseases that currently have none. The work builds on a previous study published earlier this year in eLife, and together they mark a shift in how we can model these diseases and test potential treatments at scale.

Breast cancer survivors with severe menopausal symptoms should be supported to make an informed decision about whether to have hormone replacement therapy or not, according to an interdisciplinary panel of experts including researchers from UCL.

The study, published in Menopause, provides the most comprehensive review to date on the use of hormone replacement therapy (HRT), also known as menopausal hormone therapy (MHT), in women who have been treated for breast cancer.

In experiments with mouse models of breast, pancreatic, and muscle cancers, researchers at Johns Hopkins All Children’s Hospital report new evidence that a novel means of boosting the natural immune system prevents cancer recurrence and improves survival.

The study, published in Nature Immunology, was federally funded by the National Cancer Institute/NIH.

A widely available and affordable drug has been shown to be effective in treating seriously ill COVID-19 patients, according to a new international study led by researchers at the Australian National University (ANU) in collaboration with King's College London.

The study analysed data from almost 500 patients hospitalised with COVID-19 across six countries.

Researchers from Queen Mary University of London’s School of Biological and Behavioural Sciences, using the simple fission yeast as a model, have shown that new TOR inhibitor rapalink-1 prolongs chronological lifespan.

The new study, published in Communications Biology journal by Juhi Kumar, Kristal Ng and Charalampos Rallis, sheds light on how drugs and natural metabolites can influence lifespan through the Target of Rapamycin (TOR) pathway.

A new study from researchers at The University of Texas MD Anderson Cancer Center shows that the glucose-fructose mix found in sugary drinks directly fuels metastasis in preclinical models of advanced colorectal cancer. The study was published in Nature Metabolism.

A research team led by Jihye Yun, Ph.D., assistant professor of Genetics, studied how sugary drinks may affect late-stage colorectal cancer.